All the news Showing 10 of 11 articles from: AASLD 2012Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Therapies Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study HCV New Drugs Research / 14 November 2012 Therapies Gilead May Top Rivals With Hepatitis C Therapy Results Bloomberg BusinessWeek / 14 November 2012 Interferon-free regimens Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations Abbott press release / 14 November 2012 Background liver proliferation linked to noncirrhotic HCC in patients with HCV Healio Hepatology / 13 November 2012 Therapies Achillion Provides Update on Clinical HCV Development Programs Achillion press release / 13 November 2012 Therapies Novartis' Certican succeeds in liver transplant trial Reuters / 12 November 2012 AASLD-GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients HCV New Drugs Research / 12 November 2012 Therapies Gilead, Abbott Unwrap Dueling Hep C Pill Data The Street / 12 November 2012 Therapies ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for Hepatitis C Vertex press release / 11 November 2012 Therapies Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily Vertex press release / 11 November 2012 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive